Abstract:Intense efforts are being undertaken to understand the pathophysiological mechanisms triggered after brain ischemia and to develop effective pharmacological treatments. However, the underlying molecular mechanisms are complex and not completely understood. One of the main problems is the fact that the ischemic damage is time-dependent and ranges from negligible to massive, involving different cell types such as neurons, astrocytes, microglia, endothelial cells, and some blood-derived cells (neutrophils, lymphocytes, etc.). Thus, approaching such a complicated cellular response generates a more complex combination of molecular mechanisms, in which cell death, cellular damage, stress and repair are intermixed. For this reason, animal and cellular model systems are needed in order to dissect and clarify which molecular mechanisms have to be promoted and/or blocked. Brain ischemia may be analyzed from two different perspectives: that of oxygen deprivation (hypoxic damage per se) and that of deprivation of glucose/serum factors. For investigations of ischemic stroke, middle cerebral artery occlusion (MCAO) is the preferred in vivo model, and uses two different approaches: transient (tMCAO), where reperfusion is permitted; or permanent (pMCAO). As a complement to this model, many laboratories expose different primary cortical neuron or neuronal cell lines to oxygen-glucose deprivation (OGD). This ex vivo model permits the analysis of the impact of hypoxic damage and the specific response of different cell types implicated in vivo, such as neurons, glia or endothelial cells. Using in vivo and neuronal OGD models, it was recently established that mTORC1 (mammalian Target of Rapamycin Complex-1), a protein complex downstream of PI3K-Akt pathway, is one of the players deregulated after ischemia and OGD. In addition, neuroprotective intervention either by estradiol or by specific AT2R agonists shows an important regulatory role for the mTORC1 activity, for instance regulating vascular endothelial growth factor (VEGF) levels. This evidence highlights the importance of understanding the role of mTORC1 in neuronal death/survival processes, as it could be a potential therapeutic target. This review summarizes the state-of-the-art of the complex kinase mTORC1 focusing in upstream and downstream pathways, their role in central nervous system and their relationship with autophagy, apoptosis and neuroprotection/neurodegeneration after ischemia/hypoxia.

Role of the ubiquitin–proteasome system in brain ischemia: Friend or foe?

Mechanistic exploration of ubiquitination-mediated pathways in cerebral ischemic injury

Ubiquitin-Proteasome System and Cerebral Ischemic Injury

The Role of Ubiquitin-Proteasome Pathway and Autophagy-Lysosome Pathway in Cerebral Ischemia

Role of Ubiquitin-Proteasome System in Myocardial Protection

Protein degradation pathways after brain ischemia.

The Ubiquitin Proteasome System As a Potential Target for the Treatment of Neurodegenerative Diseases

SUMOylation in brain ischemia: Patterns, targets, and translational implications

Abstract 345: Inadequate Coupling Between Ubiquitination and the Proteasome is a Major Pathogenic Factor of Myocardial Ischemia/Reperfusion Injury

Post-ischemic ubiquitination at the postsynaptic density reversibly influences the activity of ischemia-relevant kinases

Abstract WMP110: Cerebral Ischemia-Reperfusion Alters Postsynaptic Kinase Activities Through Ubiquitination

Exploration on the Mechanism of Ubiquitin Proteasome System in Cerebral Stroke

Protein aggregation and proteasome dysfunction after brain ischemia.

Role of Pericyte‐derived SENP1 in Neuronal Injury after Brain Ischemia

Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury

Role of mTORC1 Controlling Proteostasis after Brain Ischemia

Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases

ER stress and the unfolded protein response in neurodegeneration

Inadequate Ubiquitination-Proteasome Coupling Contributes to Myocardial Ischemia-Reperfusion Injury

Recent pharmacological insights on abating toxic protein species burden in neurological disorders: Emphasis on 26S proteasome activation

Interruption of Endolysosomal Trafficking After Focal Brain Ischemia